Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Merck & Co.: Clinical Trials & FDA Approval Profile

Merck & Co. (Rahway, NJ) sponsors 439 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 201 active protocols (101 recruiting now), 195 completed protocols, and 183 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.8%
Median Closed Enrollment vs National (145 pts)302 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Merck & Co.
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)439
Active Pipeline (Recruiting Now)201 (101)
Completed vs Stopped Early195 / 43 (9.8%)
Median Closed Actual Enrollment302 participants
Physical Hospital Site Disclosure99.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals183 (15 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Merck & Co.
Hospital Research SiteLocationShared Protocols
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA68
University of Colorado Anschutz Medical CampusAurora, CO55
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CT53

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Merck & Co.
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06136650A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate CancerPhase IIIRECRUITING
NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Phase IIIRECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment inPhase IIIRECRUITING
NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in ParticipanPhase IIIRECRUITING
NCT03486873Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a PembPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Merck & Co. Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI